Osteotech's Plexur P Biocomposite for the spine:
This article was originally published in Clinica
Osteotech has received US FDA 510(k) clearance for its Plexur P Biocomposite for use in the spine. The product is used as a bone filler and bone graft extender, and was cleared in the US for filling bony voids of the pelvis and extremities in February 2007. It is a composite of cortical fibres suspended in a scaffold, available as granules, cylinders, blocks, wedges and sheets. Last month, the FDA cleared the Eatontown, New Jersey-based firm's Plexur M Biocomposite for filling voids or gaps of the skeletal system that are not intrinsic to the stability of the bony structure. Plexus M is a flexible biomaterial that becomes mouldable when heated (see Clinica No 1298, p 18).
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.